WallStSmart

AbbVie Inc (ABBV)vsLaboratory Corporation of America Holdings (LH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 338% more annual revenue ($61.16B vs $13.95B). ABBV leads profitability with a 6.9% profit margin vs 6.3%. ABBV appears more attractively valued with a PEG of 0.48. LH earns a higher WallStSmart Score of 63/100 (C+).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.7Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

LH

Buy

63

out of 100

Grade: C+

Growth: 6.7Profit: 5.5Value: 6.0Quality: 6.0
Piotroski: 4/9Altman Z: 2.26
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-29.3%)

Margin of Safety

-29.3%

Fair Value

$163.42

Current Price

$203.89

$40.47 premium

UndervaluedFair: $163.42Overvalued
LHUndervalued (+7.8%)

Margin of Safety

+7.8%

Fair Value

$314.31

Current Price

$257.14

$57.17 discount

UndervaluedFair: $314.31Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$360.63B10/10

Mega-cap, among the largest globally

PEG RatioValuation
0.4810/10

Growing faster than its price suggests

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
34.1%10/10

Strong operational efficiency at 34.1%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

LH1 strengths · Avg: 8.0/10
Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
6.9%3/10

6.9% margin — thin

P/E RatioValuation
100.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-88.7%2/10

Earnings declined 88.7%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

LH1 concerns · Avg: 3.0/10
Profit MarginProfitability
6.3%3/10

6.3% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.

Bull Case : LH

The strongest argument for LH centers on Price/Book. PEG of 1.06 suggests the stock is reasonably priced for its growth.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.

Bear Case : LH

The primary concerns for LH are Profit Margin.

Key Dynamics to Monitor

LH carries more volatility with a beta of 0.98 — expect wider price swings.

ABBV is growing revenue faster at 10.0% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ABBV scores higher overall (63/100 vs 63/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Laboratory Corporation of America Holdings

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Laboratory Corporation of America Holdings, more commonly known as Labcorp, is an American company headquartered in Burlington, North Carolina. It operates one of the largest clinical laboratory networks in the world, with a United States network of 36 primary laboratories.

Visit Website →

Want to dig deeper into these stocks?